腹膜转移多见于多种腹腔实体恶性肿瘤中，难于诊断，目前尚无有效的治疗方法。前期结果提示养正消积活性成分DME25可明显抑制结肠癌、卵巢癌细胞与基质、间皮细胞的粘附，且透明质烷（HA）抑制剂可以单独或协同抑制以上的粘附作用，提示DME25可抑制HA介导的细胞粘附。进一步实验示DME25可在小鼠模型中抑制结肠癌细胞形成的腹膜转移。本研究拟进一步验证DME25对胃癌、结肠癌、胰腺癌细胞增殖、转移能力的影响；对肿瘤细胞粘附、侵袭间皮细胞能力的影响；对血管内皮细胞增殖、转移以及血管形成的影响，并探索相关机制；同时在小鼠腹腔转移体内模型中进一步验证DME25对腹膜转移的抑制作用和相关机制，并探讨其开发合理剂型、用于临床肿瘤腹膜转移治疗的前景。

Peritoneal metastasis is a frequently seen in patients with solid tumours in the peritoneal cavity and indeed a number of other organs，it is a very difficult condition to diagnose, and no effective methods was found to treat peritoneal metastasis. Our preliminary result indicate that DME25 the active component of YZXJ obviously inhibit ability of colorectal and ovarian cancer cells to adhere to ground-substance and mesothelial cells, hyaluronan (HA) inhibitor could inhibit the adherence mentined above alone or in coordination with DME25, indicating that DME25 could interrupt the adhesion process mediated by HA.Further investigation reveal that DME25 could inhibit peritoneal metastasis in ex-vivo models。In this proposal, we plan to investigate the influence of YZXJ on growth and metastasis ability of gastric cancer、colorectal cancer and pancreatic carcinoma cells, and on adhering、invading ability of tumor cells to mesothelial cells, and on growing、metastatic ability of vascular endothelial cell and angiogenesis, and further investigate the underlying mechanisms. The in-vivo model was also constructed to confirm the YZXJ's role in inhibiting peritoneal metastasis and involved mechanism, and finally deduce the potential clinical implication; and formation of a viable formulation that is viable for clinical use.